Germany· DE-A57-862a357e1f26a869
Yomesan
A niclosamide product containing niclosamide, registered in Germany by Bayer Vital Gmbh. The same ATC class is registered in 7 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Niclosamide is registered in 7 of 19 countries.
Countries holding a registration under ATC P02DA01 (niclosamide), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 4 of them publish a price we can compare per daily dose
Niclosamide · ATC P02DA01
7 / 19 countries
- Belgiumprice
- Finlandprice
- Germany
- Italyprice
- Netherlands
- Norwayprice
- United Kingdom
Price per daily dose
What a daily dose of niclosamide costs, country by country.
Normalised to the WHO defined daily dose (2 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Niclosamide · price per daily dose (2 g)
USD · FX 28 Sept 2026
- IT Italy$3.23
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Niclosamide
- Manufacturer
- Bayer Vital Gmbh
- Country
- Germany (DE)
- ATC code
- P02DA01
- ATC class
- Niclosamide
- Defined daily dose
- 2 g, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
7 interactions on record for niclosamide.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Niclosamide · interactions on record
7 records
- 1 severe
- 6 moderate
Most severe, free to view
- TizanidineM03BX02severe
- AlosetronA03AE01moderate
- DuloxetinG04BX18moderate
- BendamustineL01AA09moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Niclosamide in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumYomesan 500 mgBayer
- FinlandKontalEtnovia Oy
- United KingdomYomesan 500mg chewable tabletsImported (Germany)
- ItalyYOMESAN*4 cpr mast 500 mgBAYER AG
- NetherlandsYomesan 500 mg, kauwtablettenBayer B.V.
- NorwayYomesanBayer
- SwedenYomesan 500 mg TuggtablettBayer AB
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- Belgium · Yomesan
- Italy · Yomesan
- Luxembourg · Yomesan
- Netherlands · Yomesan
- Sweden · Yomesan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/edb34b7e-9d1d-4915-b0c2-19f871fe6f29 GET /v1/drugs/edb34b7e-9d1d-4915-b0c2-19f871fe6f29?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Niclosamide",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about niclosamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.